Advertisement
FRMM vs PRQR
Which Stock Would AI Choose? Forum Markets (FRMM) vs. ProQR Therapeutics (PRQR) Stock Comparison
Key Takeaways
- Tickeron AI Verdict: PRQR — ProQR Therapeutics' stronger recent momentum, positive clinical catalysts, and firm analyst consensus give it the relative edge over FRMM in the current environment.
- FRMM (Forum Markets) is a micro-cap digital-asset platform that has seen sharp, downward price swings amid elevated volatility and deep operating losses.
- PRQR (ProQR Therapeutics) is a clinical-stage biotech riding positive early data from its Axiomer RNA-editing platform, supported by a Strong Buy analyst consensus.
- The two companies occupy entirely different sectors — tokenized real-world assets versus RNA-based therapeutics — making this a contrast of growth drivers and risk profiles rather than direct competitors.
- Explore more on each name: FRMM Major News, FRMM Today's Price Move, PRQR Major News, and PRQR Today's Price Move.
- To see how AI trading systems are positioning across the market, explore Trending AI Robots.
Introduction
Investors weighing speculative growth opportunities are often drawn to small- and micro-cap names with outsized volatility and potential. FRMM (Forum Markets, Inc.) and PRQR (ProQR Therapeutics N.V.) both fit that profile, yet they operate in fundamentally different arenas: one in tokenized real-world assets, the other in RNA-based drug development. This stock comparison is most relevant to traders and investors who can tolerate elevated risk and who are evaluating relative performance, momentum, and market positioning. Understanding how each name responds to catalysts — and where their risk profiles diverge — can help clarify which opportunity currently aligns better with a given strategy.
FRMM Overview and Recent Performance
FRMM — Forum Markets, Inc., formerly ETHZilla Corporation — is a financial-technology company building a blockchain-based platform for acquiring, structuring, and tokenizing institutional-grade real-world assets (RWA; tangible or financial assets represented as digital tokens) on Ethereum. The company completed its rebranding and ticker change to FRMM in early March 2026 as part of a push toward institutional asset tokenization.
Recent market activity has been turbulent. After a sharp speculative surge earlier in the year, the stock has given back substantial ground, with price declining noticeably over the past month and trading far below its 52-week high. The company remains unprofitable, and its latest quarterly results showed revenue that fell short of some estimates alongside a significantly widened net loss. Management has initiated a formal strategic review and extended a share-repurchase program, developments that underscore both the company's transitional phase and the uncertainty surrounding its path to scale. High beta (a measure of a stock's sensitivity to market swings) and thin trading volumes contribute to pronounced, often rapid price moves.
PRQR Overview and Recent Performance
PRQR — ProQR Therapeutics N.V. — is a clinical-stage biotechnology company based in the Netherlands and Cambridge, Massachusetts, focused on RNA (ribonucleic acid, the molecule that carries genetic instructions) therapies built on its proprietary Axiomer RNA-editing platform. Its pipeline targets rare genetic and cholestatic liver diseases.
In recent weeks, sentiment has improved on a series of clinical and corporate developments. The company reported positive Phase 1 data for its lead candidate, AX-0810, including biomarker engagement that exceeded expectations, and dosed the first participant in a Phase 1 trial of a next-generation candidate, AX-0811. ProQR also raised capital with participation from Eli Lilly, and it brought on AI leaders to accelerate its RNA-editing pipeline. These catalysts have been reflected in a meaningful multi-week price advance and a Strong Buy consensus among covering analysts. While the company remains loss-making, its strengthened cash position provides a runway to advance its programs toward upcoming data readouts.
Trending AI Robots
Tickeron maintains a broad ecosystem of AI trading bots that monitor and trade thousands of different tickers across the market. Each bot is built around its own trading style, strategy, timeframe, performance record, and statistical profile — and each targets a distinct set of securities. Because not every bot is suited to every market regime, Tickeron curates a dedicated Trending AI Robots section that highlights the systems best aligned with current market conditions. For investors comparing names such as FRMM and PRQR, reviewing these curated strategies can offer an additional, data-driven lens on momentum and positioning. Explore the Trending AI Robots page to see which approaches are currently gaining traction.
Head-to-Head Comparison
The clearest contrast between these two stocks is their business model. FRMM is a nascent fintech venture pursuing a still-emerging market for tokenized real-world assets, with limited revenue, deep losses, and high sensitivity to both crypto sentiment and execution risk. PRQR is a more established biotech with a defined clinical pipeline, a major pharmaceutical partnership, and near-term catalysts tied to trial data.
On momentum, PRQR has the advantage, having appreciated over recent weeks and months on positive news flow, while FRMM has trended lower with elevated volatility. Risk profiles also differ: FRMM carries higher beta and thinner liquidity, magnifying downside swings, whereas PRQR faces binary, clinical-event risk common to biotech. From a sentiment standpoint, PRQR enjoys broad analyst support, while FRMM has minimal coverage and a much smaller market capitalization. Sector exposure is another differentiator — one is tied to digital assets and blockchain, the other to healthcare innovation — so their drivers rarely overlap.
Tickeron AI Verdict
Based on observable factors such as trend consistency, recent momentum, catalyst visibility, and relative positioning, Tickeron's AI would likely favor PRQR over FRMM in the current environment. ProQR's combination of positive clinical data, a strengthened balance sheet, and a firm analyst consensus points to more durable upward momentum, whereas Forum Markets' continued downtrend, deep losses, and elevated volatility suggest greater uncertainty. This assessment reflects a probabilistic, data-driven comparison rather than a definitive forecast, and market conditions can shift rapidly for both names.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FRMM is a Hold and PRQR is a Hold.
FRMM's RSI Oscillator is sitting in oversold zone for 1 day
It is expected that a price bounce should occur soon.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +7.65% 3-day Advance, the price is estimated to grow further. Considering data from situations where FRMM advanced for three days, in 173 of 204 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
FRMM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FRMM as a result. In 81 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for FRMM turned negative on November 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 43 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
The 50-day moving average for FRMM moved below the 200-day moving average on November 04, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FRMM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for FRMM entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 59 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.314) is normal, around the industry mean (-1.906). P/E Ratio (-0.060) is within average values for comparable stocks, (9.554). Projected Growth (PEG Ratio) (2.780) is also within normal values, averaging (2.824). Dividend Yield (0.000) settles around the average of (0.069) among similar stocks. P/S Ratio (7.246) is also within normal values, averaging (70.383).
The Tickeron Price Growth Rating for this company is 91 (best 1 - 100 worst), indicating slightly worse than average price growth. FRMM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FRMM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
PRQR in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 13, 2026
PRQR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 34 of 38 cases where PRQR's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where PRQR's RSI Oscillator exited the oversold zone, 24 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for PRQR just turned positive on October 28, 2026. Looking at past instances where PRQR's MACD turned positive, the stock continued to rise in 34 of 44 cases over the following month. The odds of a continued upward trend are 77%.
Following a +3.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where PRQR advanced for three days, in 173 of 209 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 50 of 59 cases where PRQR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 85%.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PRQR as a result. In 82 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The 50-day moving average for PRQR moved below the 200-day moving average on November 05, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PRQR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for PRQR entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 37 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.397) is normal, around the industry mean (3.498). P/E Ratio (-3.375) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (9.294) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 77 (best 1 - 100 worst), indicating slightly worse than average price growth. PRQR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRQR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
FRMM | PRQR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 7 | 8 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 59 Fair valued | 37 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 98 | |
PRICE GROWTH RATING 1..100 | 91 | 77 | |
P/E GROWTH RATING 1..100 | 10 | 19 | |
SEASONALITY SCORE 1..100 | n/a | 29 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PRQR's Valuation (37) in the Biotechnology industry is in the same range as FRMM (59) in the Financial Conglomerates industry. This means that PRQR’s stock grew similarly to FRMM’s over the last 12 months.
PRQR's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as FRMM (100) in the Financial Conglomerates industry. This means that PRQR’s stock grew similarly to FRMM’s over the last 12 months.
PRQR's SMR Rating (98) in the Biotechnology industry is in the same range as FRMM (100) in the Financial Conglomerates industry. This means that PRQR’s stock grew similarly to FRMM’s over the last 12 months.
PRQR's Price Growth Rating (77) in the Biotechnology industry is in the same range as FRMM (91) in the Financial Conglomerates industry. This means that PRQR’s stock grew similarly to FRMM’s over the last 12 months.
FRMM's P/E Growth Rating (10) in the Financial Conglomerates industry is in the same range as PRQR (19) in the Biotechnology industry. This means that FRMM’s stock grew similarly to PRQR’s over the last 12 months.
| FRMM | PRQR | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 83% |
| Stochastic ODDS (%) | 2 days ago 87% | 2 days ago 85% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 85% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 77% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 86% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 84% |
| Advances ODDS (%) | 8 days ago 85% | 3 days ago 83% |
| Declines ODDS (%) | 2 days ago 90% | 10 days ago 84% |
| BollingerBands ODDS (%) | 2 days ago 83% | 2 days ago 89% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 86% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
FRMM’s FA Score shows that 1 FA rating(s) are green while PRQR’s FA Score has 1 green FA rating(s).
- FRMM’s FA Score: 1 green, 4 red.
- PRQR’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
FRMM’s TA Score shows that 4 TA indicator(s) are bullish while PRQR’s TA Score has 4 bullish TA indicator(s).
- FRMM’s TA Score: 4 bullish, 5 bearish.
- PRQR’s TA Score: 4 bullish, 5 bearish.
Price Growth
FRMM (@Packaged Software) experienced а -17.78% price change this week, while PRQR (@Biotechnology) price change was -4.38% for the same time period.
The average weekly price growth across all stocks in the @Packaged Software industry was -2.44%. For the same industry, the average monthly price growth was -3.86%, and the average quarterly price growth was +4.03%.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
FRMM is expected to report earnings on Nov 12, 2026.
PRQR is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Packaged Software (-2.44% weekly)Packaged software comprises multiple software programs bundled together and sold as a group. For example, Microsoft Office includes multiple applications such as Excel, Word, and PowerPoint. In some cases, buying a bundled product is cheaper than purchasing each item individually[s20] . Microsoft Corporation, Oracle Corp. and Adobe are some major American packaged software makers.
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
FRMM and
Correlation & Price change
A.I.dvisor indicates that over the last year, FRMM has been loosely correlated with WVE. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if FRMM jumps, then WVE could also see price increases.
| Ticker / NAME | Correlation To FRMM | 1D Price Change % | ||
|---|---|---|---|---|
| FRMM | 100% | -2.08% | ||
| WVE - FRMM | 44% Loosely correlated | -2.01% | ||
| PRQR - FRMM | 44% Loosely correlated | -5.07% | ||
| JSPR - FRMM | 41% Loosely correlated | -9.90% | ||
| MSTR - FRMM | 39% Loosely correlated | -3.60% | ||
| PHUN - FRMM | 39% Loosely correlated | -2.79% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| DSMC | 44.93 | -0.03 | -0.07% |
| Distillate Small/Mid Cash Flow ETF (DSMC) | |||
| EDGX | 25.96 | -0.09 | -0.33% |
| Global X U.S. 500 Income Edge ETF (EDGX) | |||
| MSLC | 59.40 | -0.21 | -0.35% |
| Morgan Stanley Pathway Large Cap Equity ETF (MSLC) | |||
| DAK | 29.36 | -0.11 | -0.36% |
| Dakota Active Equity ETF (DAK) | |||
| MSTU | 22.72 | -1.78 | -7.27% |
| T-Rex 2X Long MSTR Daily Target ETF (MSTU) | |||